Forskning ved Københavns Universitet - Københavns Universitet


Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

  • Oliver D Howes
  • Rob McCutcheon
  • Ofer Agid
  • Andrea de Bartolomeis
  • Nico J M van Beveren
  • Michael L Birnbaum
  • Michael A P Bloomfield
  • Rodrigo A Bressan
  • Robert W Buchanan
  • William T Carpenter
  • David J Castle
  • Leslie Citrome
  • Zafiris J Daskalakis
  • Michael Davidson
  • Richard J Drake
  • Serdar Dursun
  • Helio Elkis
  • Peter Falkai
  • W Wolfgang Fleischacker
  • Ary Gadelha
  • Fiona Gaughran
  • Ariel Graff-Guerrero
  • Jaime E C Hallak
  • William G Honer
  • James Kennedy
  • Bruce J Kinon
  • Stephen M Lawrie
  • Jimmy Lee
  • F Markus Leweke
  • James H MacCabe
  • Carolyn B McNabb
  • Herbert Meltzer
  • Hans-Jürgen Möller
  • Shinchiro Nakajima
  • Christos Pantelis
  • Tiago Reis Marques
  • Gary Remington
  • Susan L Rossell
  • Bruce R Russell
  • Cynthia O Siu
  • Takefumi Suzuki
  • Iris E Sommer
  • David Taylor
  • Neil Thomas
  • Alp Üçok
  • Daniel Umbricht
  • James T R Walters
  • John Kane

OBJECTIVE: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines.

METHOD: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus.

RESULTS: Of 2,808 studies identified, 42 met inclusion criteria. Of these, 21 studies (50%) did not provide operationalized criteria. In the remaining studies, criteria varied considerably, particularly regarding symptom severity, prior treatment duration, and antipsychotic dosage thresholds; only two studies (5%) utilized the same criteria. The consensus group identified minimum and optimal criteria, employing the following principles: 1) current symptoms of a minimum duration and severity determined by a standardized rating scale; 2) moderate or worse functional impairment; 3) prior treatment consisting of at least two different antipsychotic trials, each for a minimum duration and dosage; 4) systematic monitoring of adherence and meeting of minimum adherence criteria; 5) ideally at least one prospective treatment trial; and 6) criteria that clearly separate responsive from treatment-resistant patients.

CONCLUSIONS: There is considerable variation in current approaches to defining treatment resistance in schizophrenia. The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation.

TidsskriftThe American Journal of Psychiatry
Udgave nummer3
Sider (fra-til)216-229
Antal sider14
StatusUdgivet - 1 mar. 2017

ID: 194777094